AMED GRiT grant · Biotech

J-Pharma receives AMED grant approval of up to ¥1.5 billion

The award supports the Beacon-BTC trial of an investigational treatment for biliary tract cancer.

J-Pharma announced on 30 October 2026 that the Japan Agency for Medical Research and Development (AMED) had approved its ¥1.5 billion subsidy application under the GRiT programme. The funded project began on 29 October and is scheduled to run through 31 December 2028.

The non-dilutive support is intended to advance Part A of the global Phase 3 Beacon-BTC trial of nanvuranlat, a LAT1 inhibitor being developed for biliary tract cancer. The approval follows the project’s selection in early October and establishes the subsidy ceiling; it does not represent an equity investment.

Use of funds

Global Phase 3 Beacon-BTC Part A trial of nanvuranlat for biliary tract cancer

Funding history

AMED GRiT grant · This round≤¥1.5B

Sources

  1. J-Pharma receives JPY1.5 billion AMED GRiT subsidy awardj-pharma.com · Oct 30, 2026
  2. j-pharma.com